Cargando…
011 Systemic hyperinflammation as a driver of maculopapular drug exanthema in severely ill COVID-19 patients?
Autores principales: | Mitamura, Y., Schulz, D., Kolm, I., Oro, S., Levesque, M., Maverakis, E., Akdis, C., Brüggen, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053927/ http://dx.doi.org/10.1016/j.jid.2021.02.027 |
Ejemplares similares
-
Cutaneous and systemic hyperinflammation drives maculopapular drug exanthema in severely ill COVID‐19 patients
por: Mitamura, Yasutaka, et al.
Publicado: (2021) -
028 Use of systemic immunosuppressive treatment is not related to COVID-19 infection in a retrospective review of patients in Massachusetts
por: Murphy, W., et al.
Publicado: (2021) -
032 A multicomponent skin-targeted COVID-19 vaccine elicits robust humoral and cellular immune responses
por: Balmert, S.C., et al.
Publicado: (2021) -
Acute Respiratory Illness Is Associated with Memory T Cell Differentiation and Other Immune Cell Changes in an Age-Associated Manner
por: Ugale, Shreya S., et al.
Publicado: (2023) -
Maculopapular Exanthema After the Second Dose of Evolocumab
por: Ghernautan, Victoria, et al.
Publicado: (2021)